12:00 AM
 | 
Mar 18, 2002
 |  BioCentury  |  Strategy

Millennium outsources to Paion

Despite Millennium Pharmaceutical Inc.'s acquisition of cardiovascular company Cor Therapeutics Inc., it is not as well equipped as might be expected to develop therapeutics for stroke. As a consequence, the company entered a deal last week with Paion GmbH, a company with clinical development experience for stroke treatments.

Under the deal, Paion (Aachen, Germany) gains responsibility for development, including all related costs, of MLNM's MLN519 proteasome inhibitor to treat stroke and other neurological indications. MLNM,...

Read the full 359 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >